Limitations of Guideline-Recommended Risk Stratification in Identifying MASLD Patients for Novel Drug Treatments

Franck, Martin; John, Katharina; Rau, Monika; Geier, Andreas; Sowa, Jan-Peter; Schattenberg, Joern M.; Demir, Muenevver; Wedemeyer, Heiner; Schulze-Osthoff, Klaus; Bantel, Heike

dc.contributor.author	Schulze-Osthoff, Klaus
dc.date.accessioned	2026-03-30T07:19:58Z
dc.date.available	2026-03-30T07:19:58Z
dc.date.issued	2025
dc.identifier.issn	1478-3223
dc.identifier.uri	http://hdl.handle.net/10900/177847
dc.language.iso	en	de_DE
dc.publisher	Hoboken : Wiley	de_DE
dc.relation.uri	http://dx.doi.org/10.1111/liv.70281	de_DE
dc.subject.ddc	610	de_DE
dc.title	Limitations of Guideline-Recommended Risk Stratification in Identifying MASLD Patients for Novel Drug Treatments	de_DE
dc.type	Article	de_DE
utue.quellen.id	20251118000000_01128
utue.personen.roh	Franck, Martin
utue.personen.roh	John, Katharina
utue.personen.roh	Rau, Monika
utue.personen.roh	Geier, Andreas
utue.personen.roh	Sowa, Jan-Peter
utue.personen.roh	Schattenberg, Joern M.
utue.personen.roh	Demir, Muenevver
utue.personen.roh	Wedemeyer, Heiner
utue.personen.roh	Schulze-Osthoff, Klaus
utue.personen.roh	Bantel, Heike
dcterms.isPartOf.ZSTitelID	Liver International	de_DE
dcterms.isPartOf.ZS-Issue	Article e70281	de_DE
dcterms.isPartOf.ZS-Volume	45 (9)	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE
utue.fakultaet	07 Mathematisch-Naturwissenschaftliche Fakultät	de_DE